Articles
Page 7 of 34
-
Citation: Alzheimer's Research & Therapy 2023 15:63
-
Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia
Loss of synaptic functionality has been recently identified as an early-stage indicator of neurological diseases. Consequently, monitoring changes in synaptic protein levels may be relevant for observing disea...
Citation: Alzheimer's Research & Therapy 2023 15:62 -
Mapping the long-term delayed recall-based cortex-hippocampus network constrained by the structural and functional connectome: a case-control multimodal MRI study
Connectome mapping may reveal new treatment targets for patients with neurological and psychiatric diseases. However, the long-term delayed recall based-network with structural and functional connectome is sti...
Citation: Alzheimer's Research & Therapy 2023 15:61 -
Therapeutic preference for Alzheimer’s disease treatments: a discrete choice experiment with caregivers and neurologists
Alzheimer’s disease (AD) is a major global health crisis in need of more effective therapies. However, difficult choices to optimize value-based care will need to be made. While identifying preferred therapeut...
Citation: Alzheimer's Research & Therapy 2023 15:60 -
Clusters of co-abundant proteins in the brain cortex associated with fronto-temporal lobar degeneration
Frontotemporal lobar degeneration (FTLD) is characterized pathologically by neuronal and glial inclusions of hyperphosphorylated tau or by neuronal cytoplasmic inclusions of TDP43. This study aimed at decipher...
Citation: Alzheimer's Research & Therapy 2023 15:59 -
Association of cortical and subcortical microstructure with disease severity: impact on cognitive decline and language impairments in frontotemporal lobar degeneration
Cortical and subcortical microstructural modifications are critical to understanding the pathogenic changes in frontotemporal lobar degeneration (FTLD) subtypes. In this study, we investigated cortical and sub...
Citation: Alzheimer's Research & Therapy 2023 15:58 -
Uncovering heterogeneous cognitive trajectories in mild cognitive impairment: a data-driven approach
Given the complex and progressive nature of mild cognitive impairment (MCI), the ability to delineate and understand the heterogeneous cognitive trajectories is crucial for developing personalized medicine and...
Citation: Alzheimer's Research & Therapy 2023 15:57 -
Blood pressure and dementia risk by physical frailty in the elderly: a nationwide cohort study
Midlife hypertension has been recognized as a modifiable risk factor for dementia, but association between blood pressure (BP) in late life and dementia has been inconclusive. In addition, few studies have inv...
Citation: Alzheimer's Research & Therapy 2023 15:56 -
The relationship of insulin resistance and diabetes to tau PET SUVR in middle-aged to older adults
Insulin resistance (IR) and type 2 diabetes have been found to increase the risk for Alzheimer’s clinical syndrome in epidemiologic studies but have not been associated with tau tangles in neuropathological re...
Citation: Alzheimer's Research & Therapy 2023 15:55 -
Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer’s disease
The relationship between biomarkers of metabolic syndrome and insulin resistance, plasma triglyceride/HDL cholesterol (TG/HDL-C) ratio, on the rate of cognitive decline in mild cognitive impairment (MCI) and d...
Citation: Alzheimer's Research & Therapy 2023 15:54 -
Attenuation of Alzheimer’s brain pathology in 5XFAD mice by PTH1-34, a peptide of parathyroid hormone
Alzheimer’s disease (AD) and osteoporosis are two distinct diseases but often occur in the same patient. Their relationship remains poorly understood. Studies using Tg2576 AD animal model demonstrate bone defi...
Citation: Alzheimer's Research & Therapy 2023 15:53 -
Mechanism of action deconvolution of the small-molecule pathological tau aggregation inhibitor Anle138b
A key histopathological hallmark of Alzheimer’s disease (AD) is the presence of neurofibrillary tangles of aggregated microtubule-associated protein tau in neurons. Anle138b is a small molecule which has previ...
Citation: Alzheimer's Research & Therapy 2023 15:52 -
Changes in CSF sPDGFRβ level and their association with blood–brain barrier breakdown in Alzheimer’s disease with or without small cerebrovascular lesions
CSF-soluble platelet-derived growth factor receptor beta (sPDGFRβ) is closely associated with pericyte damage. However, the changes in CSF sPDGFRβ levels and their role in blood–brain barrier (BBB) leakage at dif...
Citation: Alzheimer's Research & Therapy 2023 15:51 -
Exploring the ATN classification system using brain morphology
The NIA-AA proposed amyloid-tau-neurodegeneration (ATN) as a classification system for AD biomarkers. The amyloid cascade hypothesis (ACH) implies a sequence across ATN groups that patients might undergo durin...
Citation: Alzheimer's Research & Therapy 2023 15:50 -
Purpose in life promotes resilience to age-related brain burden in middle-aged adults
Disease-modifying agents to counteract cognitive impairment in older age remain elusive. Hence, identifying modifiable factors promoting resilience, as the capacity of the brain to maintain cognition and funct...
Citation: Alzheimer's Research & Therapy 2023 15:49 -
Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts
Cerebrospinal fluid (CSF) p-tau235 is a novel biomarker highly specific of Alzheimer’s disease (AD). However, CSF p-tau235 has only been studied in well-characterized research cohorts, which do not fully refle...
Citation: Alzheimer's Research & Therapy 2023 15:48 -
Assessment of Alzheimer-related pathologies of dementia using machine learning feature selection
Although a variety of brain lesions may contribute to the pathological assessment of dementia, the relationship of these lesions to dementia, how they interact and how to quantify them remains uncertain. Syste...
Citation: Alzheimer's Research & Therapy 2023 15:47 -
Restless leg syndrome and risk of all-cause dementia: a nationwide retrospective cohort study
Restless leg syndrome (RLS) is associated with poor sleep quality, depression or anxiety, poor dietary patterns, microvasculopathy, and hypoxia, all of which are known risk factors for dementia. However, the r...
Citation: Alzheimer's Research & Therapy 2023 15:46 -
Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer’s disease
There is a critical need for novel primary endpoints designed to detect early and subtle changes in cognition in clinical trials targeting the asymptomatic (preclinical) phase of Alzheimer’s disease (AD). The ...
Citation: Alzheimer's Research & Therapy 2023 15:45 -
Cerebrospinal fluid biomarkers of axonal and synaptic degeneration in a population-based sample
Neurofilament light (NfL) and neurogranin (Ng) are promising candidate AD biomarkers, reflecting axonal and synaptic damage, respectively. Since there is a need to understand the synaptic and axonal damage in ...
Citation: Alzheimer's Research & Therapy 2023 15:44 -
Brain reserve contributes to distinguishing preclinical Alzheimer’s stages 1 and 2
In preclinical Alzheimer’s disease, it is unclear why some individuals with amyloid pathologic change are asymptomatic (stage 1), whereas others experience subjective cognitive decline (SCD, stage 2). Here, we...
Citation: Alzheimer's Research & Therapy 2023 15:43 -
Disruption of early visual processing in amyloid-positive healthy individuals and mild cognitive impairment
Amyloid deposition is a primary predictor of Alzheimer’s disease (AD) and related neurodegenerative disorders. Retinal changes involving the structure and function of the ganglion cell layer are increasingly d...
Citation: Alzheimer's Research & Therapy 2023 15:42 -
Early tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression
There is an increasing interest in utilizing tau PET to identify patients early in Alzheimer’s disease (AD). In this work, a temporal lobe composite (Eτ) volume of interest (VOI) was evaluated in a longitudinal f...
Citation: Alzheimer's Research & Therapy 2023 15:41 -
Shared and unique effects of ApoEε4 and pathogenic gene mutation on cognition and imaging in preclinical familial Alzheimer’s disease
Neuropsychology and imaging changes have been reported in the preclinical stage of familial Alzheimer’s disease (FAD). This study investigated the effects of APOEε4 and known pathogenic gene mutation on different...
Citation: Alzheimer's Research & Therapy 2023 15:40 -
Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). Study AB09004 evaluated masitinib as an adjunct to cholinesteras...
Citation: Alzheimer's Research & Therapy 2023 15:39 -
Investigating associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease
Identifying blood-based signatures of brain health and preclinical pathology may offer insights into early disease mechanisms and highlight avenues for intervention. Here, we systematically profiled associatio...
Citation: Alzheimer's Research & Therapy 2023 15:38 -
Associations between different tau-PET patterns and longitudinal atrophy in the Alzheimer’s disease continuum: biological and methodological perspectives from disease heterogeneity
Subtypes and patterns are defined using tau-PET (tau pathology) and structural MRI (atrophy) in Alzheimer’s disease (AD). However, the relationship between tau pathology and atrophy across these subtypes/patte...
Citation: Alzheimer's Research & Therapy 2023 15:37 -
Letter to the Editor Authors’ Response: Choroid and choriocapillaris changes in early-stage Parkinson’s disease: a swept-source optical coherence tomography angiography-based cross-sectional study
Citation: Alzheimer's Research & Therapy 2023 15:36 -
Choroid and choriocapillaris changes in early-stage Parkinson’s disease: a swept-source optical coherence tomography angiography-based cross-sectional study
Citation: Alzheimer's Research & Therapy 2023 15:35 -
Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort
Alzheimer’s disease (AD) is a complex neurodegenerative disorder with β-amyloid pathology as a key underlying process. The relevance of cerebrospinal fluid (CSF) and brain imaging biomarkers is validated in cl...
Citation: Alzheimer's Research & Therapy 2023 15:34 -
Early activation of Toll-like receptor-3 reduces the pathological progression of Alzheimer’s disease in APP/PS1 mouse
Toll-like receptor 3 (TLR3) plays an important role in the immune/inflammatory response in the nervous system and is a main pathological feature of Alzheimer’s disease (AD). This study investigates the role of...
Citation: Alzheimer's Research & Therapy 2023 15:33 -
Neural biomarker diagnosis and prediction to mild cognitive impairment and Alzheimer’s disease using EEG technology
Electroencephalogram (EEG) has emerged as a non-invasive tool to detect the aberrant neuronal activity related to different stages of Alzheimer’s disease (AD). However, the effectiveness of EEG in the precise ...
Citation: Alzheimer's Research & Therapy 2023 15:32 -
The dynamics of plasma biomarkers across the Alzheimer’s continuum
Failures in drug trials strengthen the necessity to further determine the neuropathological events during the development of Alzheimer’s disease (AD). We sought to investigate the dynamic changes and performan...
Citation: Alzheimer's Research & Therapy 2023 15:31 -
Initial levels of β-amyloid and tau deposition have distinct effects on longitudinal tau accumulation in Alzheimer’s disease
To better assist with the design of future clinical trials for Alzheimer’s disease (AD) and aid in our understanding of the disease’s symptomatology, it is essential to clarify what roles β-amyloid (Aβ) plaque...
Citation: Alzheimer's Research & Therapy 2023 15:30 -
Correction: Cortical microstructure in primary progressive aphasia: a multicenter study
Citation: Alzheimer's Research & Therapy 2023 15:29 -
Recruitment across two decades of NIH-funded Alzheimer’s disease clinical trials
Timely accrual of a representative sample is a key factor in whether Alzheimer’s disease (AD) clinical trials successfully answer the scientific questions under study. Studies in other fields have observed tha...
Citation: Alzheimer's Research & Therapy 2023 15:28 -
Hippocampus-centred grey matter covariance networks predict the development and reversion of mild cognitive impairment
Mild cognitive impairment (MCI) has been thought of as the transitional stage between normal ageing and Alzheimer’s disease, involving substantial changes in brain grey matter structures. As most previous stud...
Citation: Alzheimer's Research & Therapy 2023 15:27 -
Decreased ratios of matrix metalloproteinases to tissue-type inhibitors in cerebrospinal fluid in sporadic and hereditary cerebral amyloid angiopathy
To evaluate the potential of cerebrospinal fluid (CSF) levels of matrix metalloproteinases and tissue-type inhibitors (MMP; TIMP), and ratios of MMPs to TIMPs, to function as biomarkers for sporadic or heredit...
Citation: Alzheimer's Research & Therapy 2023 15:26 -
Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit
Alzheimer’s disease (AD) is a complex and heterogeneous disease, which requires reliable biomarkers for diagnosis and monitoring disease activity. Preanalytical protocol and technical variability associated wi...
Citation: Alzheimer's Research & Therapy 2023 15:25 -
Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer’s dementia: a randomized controlled trial
This phase II proof-of-concept study assessed the efficacy and safety of BI 425809, a novel selective glycine transporter-1 inhibitor, for the treatment of cognitive impairment associated with probable Alzheim...
Citation: Alzheimer's Research & Therapy 2023 15:24 -
Altered dynamics of glymphatic flow in a mature-onset Tet-off APP mouse model of amyloidosis
Alzheimer’s disease (AD) is an incurable neurodegenerative disorder characterised by the progressive buildup of toxic amyloid-beta (Aβ) and tau protein aggregates eventually leading to cognitive decline. Recen...
Citation: Alzheimer's Research & Therapy 2023 15:23 -
How does apolipoprotein E genotype influence the relationship between physical activity and Alzheimer’s disease risk? A novel integrative model
Wide evidence suggests that physical activity (PA) confers protection against Alzheimer’s disease (AD). On the other hand, the apolipoprotein E gene (APOE) ε4 allele represents the greatest genetic risk factor fo...
Citation: Alzheimer's Research & Therapy 2023 15:22 -
Clinical features and biomarkers of semantic variant primary progressive aphasia with MAPT mutation
Semantic variant primary progressive aphasia (svPPA) is generally sporadic, with very few reports of tau pathology caused by MAPT mutations.
Citation: Alzheimer's Research & Therapy 2023 15:21 -
The beneficial effect on cognition of noninvasive brain stimulation intervention in patients with dementia: a network meta-analysis of randomized controlled trials
Dementia [i.e., Alzheimer disease (AD)], the most common neurodegenerative disease, causes profound negative impacts on executive function and quality of life. Available pharmacological treatments often fail t...
Citation: Alzheimer's Research & Therapy 2023 15:20 -
Early visual alterations in individuals at-risk of Alzheimer’s disease: a multidisciplinary approach
The earliest pathological features of Alzheimer’s disease (AD) appear decades before the clinical symptoms. The pathology affects the brain and the eye, leading to retinal structural changes and functional vis...
Citation: Alzheimer's Research & Therapy 2023 15:19 -
Correction: Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
Citation: Alzheimer's Research & Therapy 2023 15:18 -
Convergent transcriptomic and genomic evidence supporting a dysregulation of CXCL16 and CCL5 in Alzheimer’s disease
Neuroinflammatory factors, especially chemokines, have been widely reported to be involved in the pathogenesis of Alzheimer’s disease (AD). It is unclear how chemokines are altered in AD, and whether dysregula...
Citation: Alzheimer's Research & Therapy 2023 15:17 -
A novel human tau knock-in mouse model reveals interaction of Abeta and human tau under progressing cerebral amyloidosis in 5xFAD mice
Hyperphosphorylation and intraneuronal aggregation of the microtubule-associated protein tau is a major pathological hallmark of Alzheimer’s disease (AD) brain. Of special interest is the effect of cerebral am...
Citation: Alzheimer's Research & Therapy 2023 15:16 -
Impact of atrial fibrillation on the cognitive decline in Alzheimer’s disease
Atrial fibrillation (AF) is a strong risk factor for Alzheimer’s disease (AD) independent of ischemic stroke. However, the clinicopathological impact of AF on the severity of AD has not been well elucidated. W...
Citation: Alzheimer's Research & Therapy 2023 15:15 -
The effects of imaging markers on clinical trajectory in cerebral amyloid angiopathy: a longitudinal study in a memory clinic
We investigated the relevance of various imaging markers for the clinical trajectory of cerebral amyloid angiopathy (CAA) patients in a memory clinic.
Citation: Alzheimer's Research & Therapy 2023 15:14
Follow
- ISSN: 1758-9193 (electronic)